Trial Profile
A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Cefepime/tazobactam (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Wockhardt
- 22 Jul 2019 Results published in the Antimicrobial Agents and Chemotherapy.
- 25 Aug 2016 Status changed to completed.
- 25 May 2016 New trial record